DURHAM, N.C., Jan. 29, 2026 (Korea Bizwire) – Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that [...]
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental glomerulosclerosis (FSGS). Primary FSGS is a rare kidney condition in which injury and loss of podocytes, the cells responsible for the kidney’s filtration system, lead [...]
Actor and comedian, Will Forte, opens up about his brother-in-law’s journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program HD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive, and emotional symptoms1 Teva’s Honestly HD program provides educational information about [...]
Circle CVI Launches cvi42 v6.4: One Platform for Every Advanced Cardiac Imaging Need. The new cvi42 v6.4 release expands Circle CVI’s all-in-one solution, delivering advanced MR automation, comprehensive coronary plaque, PCAT, and vascular CT analysis and planning tools, with seamless integration to PowerScribe for a fully connected imaging workflow. Enhanced automation, reproducibility, and AI-driven tools enable clinicians to [...]
VANCOUVER, British Columbia, Jan. 27, 2026 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi’s 2026 Virtual Oncology Leadership Summit: Zymeworks’ management will participate in one-on-one [...]
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer’s inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million Ingelheim, Germany, and Shanghai, China, 26, January 2026 – Boehringer Ingelheim and Simcere Pharmaceutical Group Ltd. (“Simcere”) (HKEX: 2096), today announced a license and [...]
Dr. Taz to Host Countdown for a Cure’s 2026 Evening of Energy Gala ATLANTA, Jan. 23, 2026 (Korea Bizwire) – Dr. Taz Bhatia M.D., a nationally recognized integrative medicine physician, author, and founder of hol+, has partnered with nonprofit Countdown for a Cure (CFAC) to help advance awareness, education, and funding for mitochondrial research. As [...]
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAH SAN DIEGO, Jan. 22, 2026 (Korea Bizwire) – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, [...]
CHICAGO, Jan. 22, 2026 (Korea Bizwire) – Amlan® International, the animal health business of Oil-Dri® Corporation of America (NYSE: ODC), is pleased to announce the promotion of Dr. Robin Jarquin to Vice President of Sales, Latin America. In this expanded leadership role, Dr. Jarquin will leverage his deep industry experience and strong regional expertise to drive sales [...]
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with the most comprehensive suite of technologies available for rotator cuff repair (RCR). Integrity Orthopaedics is a US‑based, early‑stage commercial developer of Tendon Seam™, an innovative and disruptive biomechanical [...]